CD274 and neoplasm: Immune checkpoint inhibitors (ICIs) are a powerful class of antibody-based immunotherapies that can reinvigorate tumor-specific T cells by blocking inhibitory ligands such as PD-1/PD-L1, CTLA-4, and LAG-3 (Figure 1A).